Investigation of Transcript Variant 6 of TPD52L2 as a Prognostic and Predictive Biomarker in Basal-Like MDA-MB-231 and MDA-MB-453 Cell Lines for Breast Cancer

Figure 3

TPD52L2 impact on breast cancer patient survival and therapy response. (a–d) Kaplan–Meier curves indicate the OS, DFI, DSS, and PFI of breast cancer patients with low and high TPD52L2 levels from the BRCA cohort. (e, f) Kaplan–Meier curves indicate the OS of breast cancer patients with low and high TPD52L2 levels after treatment with radiation therapy or targeted therapy from the BRCA cohort (log-rank test, ).

(a)

(b)

(c)

(d)

(e)

(f)